Shimadzu Corporation Q3 FY2026 earnings call

• Corporate Purpose & Strategic Focus: The company's core mission is to achieve 'Planetary Health' (health for people and the Earth), with four priority business domains: Healthcare, Green, Materials, and Industry. It operates under a medium-term management plan with the goal of becoming an innovative company that solves social issues with global partners to achieve sustainable growth.
• Healthcare Domain Priorities: Prioritizes growth in the pharmaceutical analytical instrumentation market, which is growing at an 8% annual average and projected to reach $340 billion by 2028. Shimadzu focuses on expanding sales of analytical equipment for existing small molecule drugs and fast-growing new categories including middle-molecule and nucleic acid drugs. To expand share in the large, fast-growing North American pharmaceutical market, Shimadzu opened 3 new R&D facilities (1 R&D center and 1 application development center each on the US west and east coast) in April 2024, has launched co-developed products that have already enabled sales to 6 previously untapped major pharmaceutical firms, and is expanding pharmaceutical-focused sales and marketing resources. The company is also advancing research on Alzheimer's disease early diagnosis via high-precision mass spectrometry blood testing and a combined blood/PET testing two-pronged approach, and conducting joint research on osteoporosis prevention and aging prevention to advance healthy longevity.
• Green Domain Priorities: Shimadzu is developing full analytical solutions for microplastic research including automated pretreatment systems and standardizing analysis methods, and supporting research into biodegradable plastics to address plastic pollution. It is also co-developing an autonomous AI-robotics experimental system for smart cell development for bio-manufacturing, a key technology for carbon neutrality projected to become a 200 trillion yen market by 2030.
• Industry Domain Growth: Turbo molecular pumps are growing alongside expanding global semiconductor demand driven by generative AI and 6G development. In aerospace equipment, defense-related revenue is growing alongside Japan's increasing defense budget, while civilian aerospace demand has exceeded pre-COVID levels as global air travel recovers.
• Overseas Expansion: Overseas revenue grew 60% over the past 5 years, reaching nearly 60% of total revenue in fiscal 2023. The Indian business grew rapidly to exceed 17 billion yen revenue in fiscal 2023, with a 20 billion yen target for fiscal 2024, long-term targets of 35 billion yen by 2030 and 47 billion yen by 2035. Shimadzu is building a new factory in Bengaluru, India with 2.5 billion yen investment, scheduled to start operation in spring 2027, initially producing measuring instruments with future expansion to medical devices and turbo molecular pumps to meet growing demand.
• Shareholder Return: The company targets maintaining a payout ratio of 30% or higher. For fiscal 2024, it plans an 11th consecutive year of dividend increases to 62 yen per share, for a 31.5% payout ratio, and completed a 25 billion yen share buyback.

1. Analytical and Measuring Instruments Segment: This is Shimadzu's core business, accounting for over 60% of total revenue and 80% of total profit. Approximately 20% of the segment's revenue comes from the pharmaceutical market. Liquid chromatography, a key product of the segment, holds the No.1 market share in India and is growing faster than the overall market during the COVID-19 pandemic.
2. Medical Equipment Segment: The segment's main products are X-ray-based diagnostic imaging systems, with core strengths of low radiation exposure and clear imaging.
3. Industrial Equipment Segment: The main product is turbo molecular pumps used primarily in semiconductor manufacturing equipment. 2019 revenue was ~17 billion yen, growing to ~32 billion yen in fiscal 2023, doubling in 5 years, and is on track to exceed that in fiscal 2024. The segment holds 40%-50% global market share for magnetic levitation turbo molecular pumps for semiconductor manufacturing, and high-margin maintenance services are a key profit driver.
4. Aerospace Equipment Segment: 80% of segment revenue comes from defense-related products and 20% from civilian aerospace. 2019 revenue was 30 billion yen with 0.8 billion yen operating profit; the 2024 fiscal year target is 35 billion yen revenue and 5 billion yen operating profit, a 6x increase in profit from 2019.

• Fiscal 2024 full year guidance: Targets 540 billion yen total revenue and 73 billion yen operating profit.
• Medium-term (fiscal 2025) targets: Maintains previously set targets of 550 billion yen total revenue, 80 billion yen operating profit, 14.5% operating margin, 11%+ ROIC, and 12.5%+ ROE.
• Turbo molecular pump guidance: Expects continued revenue growth in line with expanding global semiconductor demand driven by generative AI and 6G development.
• Aerospace equipment guidance: Expects continued growth in both defense-related revenue (driven by Japan's increasing defense budget) and civilian aerospace revenue (driven by air travel demand exceeding pre-COVID levels).
• Indian business guidance: Targets 20 billion yen fiscal 2024 revenue, 35 billion yen revenue by 2030, and 47 billion yen by 2035.

• No specific major operational risks are explicitly discussed in the available transcript. Management noted that the core analytical instrumentation and high-growth healthcare markets are inherently resilient to economic downturns, so any negative impact of a potential U.S. or global recession would be mitigated.

Q: What is the key reason Shimadzu has survived and thrived for 150 years, and will there be a special commemorative dividend for the 150th anniversary?

A: Management attributes 150 years of success to two core strengths: the ability to adapt to changing social trends and address emerging societal needs, and consistent long-term investment in developing technical capabilities to meet those needs. Management states that a commemorative dividend is not confirmed at this time, but any plan for a special dividend will be publicly announced if approved.

Q: Who are Shimadzu's main competitors in analytical instrumentation, and what are Shimadzu's competitive advantages and global growth strategy?

A: The main global competitors are four U.S.-based firms: Waters, Agilent, Thermo Fisher, and Danaher, competing in a global top 5 market alongside Shimadzu. Shimadzu's key advantages are faster analysis speed, stable consistent data output, and an extensive full product line that enables total end-to-end analytical solutions that competitors cannot match. The company's strategy is to grow share in large developed markets (North America and Europe) by developing products and services tailored to local customer needs.

Q: Why is Shimadzu prioritizing the North American pharmaceutical market, and what are the early results from new R&D facilities?

A: North America is the world's largest and most innovative pharmaceutical market, where Shimadzu currently holds low market share leaving significant room for growth. Additionally, North American pharmaceutical industry trends spread to Asian markets (where Shimadzu already has strong positions), so products proven in North America can help drive growth across the entire Asian region. The new facilities were just opened in April 2024, so tangible financial results are still in the future, but development projects are increasing on schedule and aligned with management expectations, with further details to be shared in the next medium-term management plan.

Q: If a severe global recession occurs, can Shimadzu maintain stable profits?

A: Shimadzu's core measuring instruments business and core focus healthcare market have inherent characteristics that make them resilient to economic cycles, so the negative impact of any recession on company earnings will be moderate.